pnt2002
PeptideexperimentalImaging agent
Clinical trial activity
6 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Feb 25, 2021 (NCT04647526)
Timeline
Indications
Mechanism of action
- Glutamate carboxypeptidase IIBINDING AGENT
FOLH1 binding agent
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06322576 | Phase 2 | Dec 31, 2024 | Adenoid Cystic Carcinoma Research Foundation, Johns Hopkins University, Progenics |
| NCT06361810 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2024 | Johns Hopkins University, Lantheus Medical Imaging, Merck |
| NCT05496959 | Phase 2 | Sep 2, 2022 | POINT Biopharma, University of California, Los Angeles |
| NCT05230251 | Phase 2 | Mar 17, 2022 | London Health Sciences Foundation, University of Western Ontario |
| NCT04647526 | Phase 3 | Feb 25, 2021 | POINT Biopharma |
| NCT06033001 | N/A | — | Lantheus Medical Imaging, POINT Biopharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| POINT Biopharma | For profit | 3 | 1 | 3 | 2021 |
| Johns Hopkins University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Lantheus Medical Imaging | For profit | 2 | 1 | 2 | 2024 |
| Adenoid Cystic Carcinoma Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2024 |
| London Health Sciences Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
| Progenics | For profit | 1 | 0 | 1 | 2024 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Western Ontario | Academic/Hospital | 1 | 1 | 1 | 2022 |
9 organizations
Page 1 / 1